Cambridge Investment Research Advisors
XBI icon

Cambridge Investment Research Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Buy
112,225
+28,487
+34% +$3.85M 0.04% 436
2026
Q1 		$10.7M Sell
83,738
-33,430
-29% -$4.17M 0.03% 587
2025
Q4 		$14.3M Buy
117,168
+68,203
+139% +$7.82M 0.04% 464
2025
Q3 		$4.91M Sell
48,965
-3,761
-7% -$339K 0.01% 931
2025
Q2 		$4.37M Sell
52,726
-6,816
-11% -$544K 0.01% 932
2025
Q1 		$4.83M Sell
59,542
-5,860
-9% -$524K 0.02% 826
2024
Q4 		$5.89M Sell
65,402
-5,726
-8% -$555K 0.02% 714
2024
Q3 		$7.03M Buy
71,128
+2,250
+3% +$221K 0.02% 635
2024
Q2 		$6.39M Sell
68,878
-7,297
-10% -$654K 0.02% 642
2024
Q1 		$7.23M Buy
76,175
+10,176
+15% +$944K 0.03% 579
2023
Q4 		$5.89M Sell
65,999
-11,130
-14% -$827K 0.03% 623
2023
Q3 		$5.63M Sell
77,129
-34,096
-31% -$2.72M 0.03% 600
2023
Q2 		$9.25M Buy
111,225
+36,234
+48% +$3.03M 0.04% 407
2023
Q1 		$5.71M Buy
74,991
+6,872
+10% +$570K 0.03% 571
2022
Q4 		$5.65M Sell
68,119
-829
-1% -$67.1K 0.03% 555
2022
Q3 		$5.47M Sell
68,948
-125,447
-65% -$10.6M 0.03% 529
2022
Q2 		$14.4M Buy
194,395
+140,122
+258% +$10.5M 0.08% 248
2022
Q1 		$4.88M Sell
54,273
-15,238
-22% -$1.41M 0.02% 643
2021
Q4 		$7.78M Buy
69,511
+7,109
+11% +$857K 0.03% 472
2021
Q3 		$7.84M Buy
62,402
+128
+0.2% +$16.5K 0.04% 431
2021
Q2 		$8.43M Sell
62,274
-18,836
-23% -$2.48M 0.04% 423
2021
Q1 		$11M Buy
81,110
+5,681
+8% +$851K 0.06% 304
2020
Q4 		$10.6M Buy
75,429
+16,502
+28% +$2.11M 0.06% 291
2020
Q3 		$6.57M Buy
58,927
+3,664
+7% +$411K 0.04% 383
2020
Q2 		$6.19M Buy
55,263
+18,149
+49% +$1.79M 0.05% 377
2020
Q1 		$2.87M Sell
37,114
-11,029
-23% -$977K 0.03% 531
2019
Q4 		$4.58M Buy
48,143
+7,639
+19% +$661K 0.04% 499
2019
Q3 		$3.09M Sell
40,504
-861
-2% -$71.6K 0.03% 591
2019
Q2 		$3.63M Buy
41,365
+346
+0.8% +$29.5K 0.03% 513
2019
Q1 		$3.71M Buy
41,019
+2,083
+5% +$177K 0.04% 473
2018
Q4 		$2.79M Sell
38,936
-30,980
-44% -$2.5M 0.03% 520
2018
Q3 		$6.7M Sell
69,916
-13,919
-17% -$1.35M 0.06% 292
2018
Q2 		$7.98M Buy
83,835
+44,412
+113% +$4.08M 0.08% 233
2018
Q1 		$3.46M Buy
39,423
+13,718
+53% +$1.25M 0.04% 427
2017
Q4 		$2.18M Sell
25,705
-8,277
-24% -$693K 0.03% 556
2017
Q3 		$2.94M Buy
33,982
+7,796
+30% +$625K 0.04% 411
2017
Q2 		$2.02M Buy
26,186
+3,212
+14% +$228K 0.03% 514
2017
Q1 		$1.59M Buy
22,974
+724
+3% +$48.6K 0.03% 526
2016
Q4 		$1.32M Buy
22,250
+9,027
+68% +$557K 0.02% 564
2016
Q3 		$877K Sell
13,223
-223
-2% -$13.8K 0.02% 745
2016
Q2 		$727K Buy
13,446
+437
+3% +$23.9K 0.02% 757
2016
Q1 		$672K Sell
13,009
-532
-4% -$27.6K 0.02% 750
2015
Q4 		$951K Buy
13,541
+1,017
+8% +$69.4K 0.02% 565
2015
Q3 		$780K Sell
12,524
-15,463
-55% -$1.22M 0.02% 567
2015
Q2 		$2.35M Sell
27,987
-1,533
-5% -$119K 0.07% 283
2015
Q1 		$2.22M Buy
29,520
+5,211
+21% +$364K 0.06% 293
2014
Q4 		$1.51M Buy
24,309
+3,897
+19% +$222K 0.05% 361
2014
Q3 		$1.06M Sell
20,412
-417
-2% -$21.3K 0.03% 499
2014
Q2 		$1.07M Sell
20,829
-94,854
-82% -$4.28M 0.04% 440
2014
Q1 		$5.49M Buy
115,683
+70,281
+155% +$3.6M 0.21% 105
2013
Q4 		$1.97M Buy
45,402
+10,257
+29% +$425K 0.08% 240
2013
Q3 		$1.51M Buy
35,145
+6,777
+24% +$275K 0.07% 270
2013
Q2 		$986K Buy
+28,368
New +$997K 0.05% 324

Other funds holding XBI

PR
PSP Research Newtown Square, Pennsylvania $188M AUM
WT
Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
WAM
Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
NHFG
New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

Cambridge Investment Research Advisors's XBI Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 34% in Q2 2026, buying an estimated $3.85M and bringing the position to 112,225 shares worth $17.8M. The position accounts for 0.04% of the portfolio, ranked #436.

Cambridge Investment Research Advisors first reported a position in XBI in Q2 2013 and has held it in 53 quarters since. 326 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Cambridge Investment Research Advisors held 112,225 shares of State Street SPDR S&P Biotech ETF worth $17.8M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 28,487 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $3.85M.
  • State Street SPDR S&P Biotech ETF made up 0.04% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #436 holding.
  • Cambridge Investment Research Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 53 quarters since.
  • 326 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.